Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit due to alleged violations of the Securities Act of 1933 related to its IPO, with claims that the offering documents were misleading regarding safety concerns and clinical trial expectations [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Soto v. BioAge Labs, Inc., allows purchasers of BioAge Labs stock from its IPO on September 26, 2024, to seek lead plaintiff status by March 10, 2025 [1][5]. - BioAge Labs sold 12.65 million shares at $18.00 per share during its IPO [2]. - The lawsuit alleges that the IPO documents falsely indicated no safety concerns and optimistic expectations for the STRIDES clinical trial [3]. Group 2: Impact of Clinical Trial Results - On December 6, 2024, BioAge Labs announced the discontinuation of the STRIDES Phase 2 study due to liver transaminitis observed in subjects, leading to a stock price drop of over 76% [4]. - By the time the class action lawsuit commenced, BioAge Labs stock was trading around $5.82 per share, significantly lower than the IPO price of $18.00 [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and has a strong track record in securities fraud cases, having recovered $6.6 billion for investors in related cases [6].
INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIOA